Korro Bio (KRRO) Long-Term Deferred Tax (2018)

Korro Bio (KRRO) posted Long-Term Deferred Tax of $12.2 million for Q4 2018.

Korro Bio (KRRO) Long-Term Deferred Tax (2018) Analysis & Trends

Korro Bio's Long-Term Deferred Tax history runs 1 years deep, the most recent figure standing at $12.2 million for Q4 2018.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $12.2 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $12.2 million (changed N/A YoY) and the FY2018 annual result came in at $12.2 million, changed N/A from the prior year.
Long-Term Deferred Tax was $12.2 million for Q4 2018 at Korro Bio.
Across five years, Long-Term Deferred Tax topped out at $12.2 million in Q4 2018 and bottomed at $12.2 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Korro Bio	123.70 Mn	9.73 Mn	-

Download Data

Date	Value
Dec 31, 2018	12.23 Mn